Physician profile
Srisai Gowda
NPI 1801995352
$10,083.94
in general payments reported to CMS, 2019-2025
33 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $1,831 · 2021: $1,712 · 2022: $1,277 · 2023: $1,435 · 2024: $1,455 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,355 · Education: $54.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,354.95 |
| Education | $54.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,488.90 | 2021-2025 | |
| Allergan, INC. | $1,596.73 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $847.31 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $813.66 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $565.39 | 2019-2025 | Spravato, Invega |
| Neurocrine Biosciences, INC. | $556.79 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $451.93 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $385.41 | 2023-2025 | Auvelity |
| Alkermes, INC. | $335.64 | 2020-2023 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $324.42 | 2019-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $245.70 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $203.15 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $199.17 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $198.93 | 2019-2025 | Fanapt, Hetlioz |
| Eisai INC. | $122.87 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $103.21 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $97.30 | 2019-2024 | Jornay Pm |
| Indivior INC. | $81.14 | 2019-2025 | Sublocade |
| Jazz Pharmaceuticals INC. | $77.88 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $49.39 | 2020-2022 | |
| Corium, LLC | $48.68 | 2022-2024 | Azstarys |
| Adlon Therapeutics L.P. | $41.84 | 2019-2021 | |
| Orexo US, INC. | $41.38 | 2019-2020 | |
| Neos Therapeutics, LP | $32.52 | 2022-2025 | Adzenys Xr-Odt |
| Alfasigma USA, INC. | $28.88 | 2021-2022 | |
| Uswm, LLC | $25.62 | 2022 | |
| Livanova USA, INC. | $24.37 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Shire North American Group INC | $23.93 | 2019 | |
| Janssen Scientific Affairs, LLC | $17.33 | 2025 | Spravato |
| Bioxcel Therapeutics, INC. | $15.09 | 2024 | Igalmi |
| Bausch Health US, LLC | $14.68 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.39 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srisai Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.